Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
This is a 13-year-old non-emergency medical transportation (NEMT) business operating across a multi-county service area in upstate New York. It moves Medicaid-eligible riders to dialysis, treatment programs, clinic appointments, hospital discharges, and outpatient care using a fleet of 53 ambulatory and wheelchair-capable vehicles and roughly 48 drivers. The customer is effectively the state: trips are assigned and paid through New York's Medicaid transportation manager and state fiscal agent, which makes the top line unusually verifiable against third-party remittance records rather than seller-prepared books.
The growth story here is real and specific. Revenue climbed from $2.39M in 2023 to $2.73M in 2024 to $4.53M in 2025, driven not by rate hikes or acquisitions but by the award of seven preferred provider zones with staggered start dates from November 2024 through January 2025. Monthly billings stepped up in exact lockstep with those go-live dates, and the July/August 2026 settled remittance weeks are running at an annualized pace near $5.05M. Those zones carry per-leg rates above the general assigned rate, roughly 41% of per-leg revenue is earned above the base ambulatory rate, and all nine zone and destination pairings received a further rate increase effective July 2026.
What makes this notable is the combination of demonstrated payment realization (100.7% of billed charges collected across five audited weeks, denial leakage near zero) and a genuinely light owner role. The former-CPA owner works a partial day handling state correspondence, escalated incidents, and vehicle policy, while dispatch, billing, maintenance, and bookkeeping run on staff expected to stay. Barriers to entry are meaningful: provider enrollment, driver and vehicle compliance, insurance, and a clean audit record that the state transportation manager rewards with assigned work.
Why we like it
- Earnings quality is exceptional for an SMB because the payer is a state fiscal agent and revenue is verifiable against third-party remittances: $481,884 billed versus $485,488 paid across five weeks, a 100.7% realization with denial leakage near zero. A buyer can validate the top line without trusting the seller's books, which is rare and de-risks the entire deal. Cash flow of $835,673 on $4.53M revenue is a healthy 18.4% margin for asset-based transport.
- The moat is structural, not marketing. Trip assignment flows through a single state-designated transportation manager that favors operators with clean audit records, adequate fleet capacity, and reliable acceptance of assigned work, and only three other ambulatory competitors serve the area. Provider enrollment, driver/vehicle compliance, and insurance are real barriers that a new entrant cannot clear quickly.
- Demand is genuinely recession-proof and recurring. Volume is driven by Medicaid enrollment and outpatient treatment (dialysis riders come multiple times a week, indefinitely), not discretionary spending, so it holds through downturns. The seven awarded zones are less than two years old and not yet at full utilization, meaning growth is already contracted and in motion rather than hypothetical.
- The operator advantage is unusually favorable. The owner works a partial day in a high-level capacity while dispatch, billing, administration, maintenance, and bookkeeping are staff-run, so the business does not depend on the seller's daily execution. Wheelchair-capable capacity sits at just two units against materially more demand, and wheelchair legs bill at a premium, so obvious near-term upside exists by adding the right vehicles.
- The zone awards carry negotiated per-leg rates above the general assigned rate, and all nine zone and destination pairings got a further rate increase effective July 2026. That means the run rate is set to improve on pricing alone before any volume growth, and 41% of per-leg revenue already comes from above-base work.
How to improve it
- Add wheelchair-capable capacity immediately. The company runs just two wheelchair units against a service area with materially more wheelchair demand than it can serve, and wheelchair legs bill at a substantial premium to ambulatory. Financing three to five additional wheelchair vans is the single highest-return use of capital in the first 90 days.
- Push utilization of the seven awarded zones toward capacity. These zones are less than two years old and not yet fully utilized, so the near-term play is filling routes and adding drivers rather than winning new work. Model the incremental driver labor against the above-base per-leg rates to size the driver bench correctly.
- Apply for additional preferred provider zones through the same state counterparty the company already deals with directly. Growth here is available by application to a relationship the business already has in good standing, with no new sales channel to build. Line up fleet and driver capacity ahead of any new award so start dates translate to billings without lag.
- Optimize working capital around the receivables cycle. Because the payer is a state fiscal agent with near-100% realization, financing receivables cheaply directly funds fleet expansion. Establish a revolving line secured against these highly predictable Medicaid remittances to fund vehicle purchases without diluting equity.
- Formalize and document the owner-dependent functions before the owner exits. His role is limited to state correspondence on territory and rates, escalated incidents, and vehicle policy, but the state relationship is the crown jewel. Build a documented playbook and introduce a designated staff or new-owner point of contact to the transportation manager during transition.
- Refinance or retire the $706,095 in vehicle notes and $608,764 FF&E at closing on favorable terms. Cleaning up the fleet financing improves free cash flow and simplifies the balance sheet for a future strategic sale. Compare owning versus leasing the incremental fleet to hold down fixed cost through the winter trough.
- Explore expansion of the direct long-distance rehabilitation discharge relationship, currently about 10% of revenue under a single provider. Higher-value long-distance legs diversify the mix beyond assigned Medicaid trips and deepen a hospital-side relationship. Assess concentration risk before leaning harder on this single counterparty.
Diligence notes
- Confirm the durability of the seven preferred provider zone awards: verify contract terms, renewal mechanics, term length, and any performance conditions with the state Medicaid transportation manager. The entire growth thesis and 41% of above-base per-leg revenue rests on these awards, so understand whether they can be reassigned, reduced, or lost on audit findings. Also validate the July 2026 rate increase in writing.
- Reconcile the audited remittance data yourself. Pull the state fiscal agent payment records directly and tie billed charges to cash remitted across a longer window than the five weeks presented, since all figures are unaudited and subject to verification. Confirm the ~$97,098 weekly run rate holds beyond the July/August 2026 sample.
- Scrutinize revenue concentration and payer risk. Roughly 90% of revenue depends on Medicaid trip assignment through one state-designated manager, plus a single provider relationship for the 10% long-distance segment. Model the downside of a Medicaid rate cut, a state budget or reimbursement policy change, or loss of the long-distance counterparty.
- Verify fleet condition, ownership, and financing. Only 42 of 53 vehicles are owned at $608,764 fair market value, with the balance financed or leased and $706,095 in vehicle notes outstanding at June 2026. Inspect the service files, assess remaining useful life and near-term capex, and confirm how the notes and leases will be handled at closing.
- Test the staff-run operating claim. Confirm that dispatch, billing, administration, maintenance, and bookkeeping staff are genuinely capable and committed to stay, since the light-owner thesis depends on it. Review driver retention, the full-time versus part-time mix used to manage the winter trough, and any wage pressure or turnover in a tight driver labor market.
- Investigate the captive insurance program and compliance record. Incurred claims fell from $310,000 in 2023 to $23,000 year to date 2026, which is favorable but worth understanding for sustainability and structure. Confirm provider enrollment is in good standing with no pending audits, recoupments, or compliance actions, given that the state rewards clean records with assigned work.
Source
Want the full analysis on every deal? Unlock the complete platform with Accredited Pro to screen live listings and read our operator-level writeups.